Idiopathic chronic pancreatitis: Beyond antioxidants.

Abstract

Chronic pancreatitis (CP) is a complex disease associated with gene-gene or gene-environment interactions. The incidence of idiopathic CP has shown an increasing trend, withits phenotypeshaving changed considerably in the last two decades. The diseaseitself can be regulated before it reaches the stage of established CP; however, the etiopathogenesis underlying idiopathic CP remains to be established, making the condition difficult to cure. Unfortunately, there also remains a lack of consensus regarding the beneficial effects of antioxidant therapiesfor CP. It is known that antioxidant therapy does not reduce inflammatory and fibrotic cytokines, making it unlikely that they could modulate the disease process. Although antioxidants are safe, very few studies to date have reported the long-term beneficial effects in patients with CP. Thus, studies are being performed to identify drugs that can improve symptoms and alter the natural history of CP. Statins, with their numerous pleiotropic effects, may play a role in the treatment of CP, butin 2006, their use was found to be associated with the undesirable side effect of promoting pancreatitis. Latter studies showed favourable effects of statins in CP, highlighting the particular benefits of lipophilic statins, such as lovastatin and simvastatin, over the hydrophilic statins, such as rosuvastatin. Ultimately, studies to repurpose N-acetylcysteine as a CP therapy areyielding very promising results.

• Authors: Rajiv M Mehta, Stephen J Pandol, Prachi R Joshi
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 27 Issue 43 Pg. 7423-7432 (Nov 21 2021) ISSN: 2219-2840 [Electronic] United States
• PMID: 34887640 (Publication Type: Editorial)
• Copyright: ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Chemical References

• Antioxidants
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Rosuvastatin Calcium

Topics

• Antioxidants (therapeutic use)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Pancreatitis, Chronic (drug therapy)
• Rosuvastatin Calcium